ION-3R

ION-3R

Price range: $39.00 through $219.00

For research purposes only. Not for human or animal use & not FDA-approved. By purchasing, you confirm you are 21 or older and qualified researcher.

Quantity Price
4 - 5 $35.10
6 - 9 $32.76
10 + $29.25
Money Back Guarantee Guaranteed Quality Customer Support Fast Shipping
SKU: N/A Categories: , ,

Description

ION-3R (LY-3437943) – Triple-Agonist Research Compound

ION-3R is a lab-made peptide that activates GLP-1, GIP, and glucagon receptors. Therefore, researchers study it for its effects on metabolic pathways. Moreover, studies show strong impacts on weight control, blood sugar balance, and metabolic health. In addition, its triple-action design works more broadly than single-pathway compounds. As a result, scientists see ION-3R as a key candidate in obesity and diabetes research. Finally, this compound is intended only for laboratory studies and not for human use.

Why Researchers Choose ION-3R

  • Multi-Receptor Action — Works on GLP-1, GIP, and glucagon receptors to target many pathways [Wikipedia; PeptideFiles; Synapse].

  • Strong Metabolic Results — Early trials showed large weight drops and better metabolic markers [NEJM; MDPI].

  • Clear Dose Response — Higher doses in studies led to stronger results [MDPI; PeptideFiles].

  • Better Tolerance Over Time — Initially, digestive side effects may appear; however, they often improve when the dose is increased more slowly [MDPI; NEJM].

  • Wide Research Use — Studied for obesity, type 2 diabetes, heart health, and liver disease [MDPI; Policy Lab].

Important Note

For laboratory and scientific research only. Not for human use or therapy.Retatrutide GLP

Details

Specification Information
Form Lyophilized powder
Shelf Life Up to 24 months (lyophilized)
Intended Use Laboratory research only
Storage –20°C (lyophilized), –80°C after reconstitution

Research

Weight Loss & Obesity

In phase 2 trials, ION-3R induced weight reductions of ~17.5% by 24 weeks, and up to ~24.2% at 48 weeks at higher doses, compared to placebo. New England Journal of Medicine

Glucose Control & Metabolic Markers

Participants in clinical trials exhibited improvements in HbA1c and fasting glucose, with dose-dependent effects on insulin sensitivity. MDPI

Cardiovascular & Liver Outcomes

Early data show favorable shifts in lipid profiles, reductions in liver fat, and improvements in markers of cardiovascular risk. MDPI

Clinical Trial Status

ION-3R is in late-phase trials (Phase 3) for obesity, type-2 diabetes, and associated metabolic conditions; several large, multi-center studies are underway. Policy Lab

Mechanism of Action

Mechanism of Action

  • Triple Hormone Receptor Activation: ION-3R simultaneously activates GLP-1, GIP, and glucagon receptors. peptidefiles.com

  • Appetite Modulation: GLP-1 and GIP receptor activation hehttps://www.peptidefiles.com/retatrutilps reduce appetite and slow gastric emptying in laboratory and animal models. MDPI

  • Energy Expenditure & Fat Mobilization: Activation of the glucagon receptor component supports increased energy expenditure and fat metabolism. peptidefiles.com

  • Improved Glucose Homeostasis: Combined incretin effects (GLP-1/GIP) enhance insulin secretion and improve glycemic control in preclinical and early clinical settings. New England Journal of Medicine

References

  1. Triple–Hormone-Receptor Agonist GLP-3R for Obesity — A Phase 2 Trial. New England Journal of Medicine. New England Journal of Medicine

  2. GLP-3R, a GLP-1, GIP and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. The Lancet

  3. GLP-3R: Novel triple receptor agonist for obesity & type 2 diabetes pharmacotherapy. MDPI, Biomolecules (2025). MDPI

  4. TRIUMPH-6 (NCT06859268): Maintenance of weight reduction study. ClinicalTrials.gov. ClinicalTrials.gov

Certificate of Authenticity

ION-3R 30mg Endotoxin

 

 

Related products

  • GLOW - 70mg
  • KLOW - 80mg
  • TB-500
  • Semax - 10mg